These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33454205)

  • 1. Endovascular Therapy for Arteriogenic Erectile Dysfunction With a Novel Sirolimus-Eluting Stent.
    Schönhofen J; Räber L; Knöchel J; Keo HH; Regli C; Kostal F; Schumacher MC; Sammarchi L; Bechir M; Diehm N
    J Sex Med; 2021 Feb; 18(2):315-326. PubMed ID: 33454205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Outcomes of Drug-Eluting Stent Implantation for Patients With Atherosclerotic Erectile Dysfunction not Responding to PDE-5-Inhibitors.
    Mohan V; Schönhofen J; Hoppe H; Schumacher M; Keo HH; Bechir M; Kalka C; Burkhard Rn M; Diehm N
    J Endovasc Ther; 2023 Jun; ():15266028231183775. PubMed ID: 37365869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endovascular Therapy for Erectile Dysfunction-Who Benefits Most? Insights From a Single-Center Experience.
    Diehm N; Marggi S; Ueki Y; Schumacher D; Keo HH; Regli C; Do DD; Moeltgen T; Grimsehl P; Wyler S; Schoenhofen H; Räber L; Schumacher M
    J Endovasc Ther; 2019 Apr; 26(2):181-190. PubMed ID: 30741067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Recoil After Balloon Angioplasty of Erection-Related Arteries in Patients With Arteriogenic Erectile Dysfunction.
    Diehm N; Do DD; Keo HH; Boerlin J; Regli C; Schumacher M; Jungmann PM; Raeber L; Baumann F
    J Endovasc Ther; 2018 Dec; 25(6):710-715. PubMed ID: 30343612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zotarolimus-eluting peripheral stents for the treatment of erectile dysfunction in subjects with suboptimal response to phosphodiesterase-5 inhibitors.
    Rogers JH; Goldstein I; Kandzari DE; Köhler TS; Stinis CT; Wagner PJ; Popma JJ; Jaff MR; Rocha-Singh KJ
    J Am Coll Cardiol; 2012 Dec; 60(25):2618-27. PubMed ID: 23177300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rationale and design of the sirolimus eluting balloon utilization for treatment of vasculogenic erectile dysfunction: the SUASION Registry.
    Matteucci A; Benedetto D; Bonanni M; Massaro G; Russo D; Russo G; Chiricolo G; Biondi-Zoccai G; Sangiorgi G
    Minerva Cardiol Angiol; 2023 Jun; 71(3):349-358. PubMed ID: 36468761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes in Patients Treated With Thin-Strut, Very Thin-Strut, or Ultrathin-Strut Drug-Eluting Stents in Small Coronary Vessels: A Prespecified Analysis of the Randomized BIO-RESORT Trial.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; van der Heijden LC; Kok MM; Danse PW; Schotborgh CE; Scholte M; de Man FHAF; Linssen GCM; von Birgelen C
    JAMA Cardiol; 2019 Jul; 4(7):659-669. PubMed ID: 31111862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study.
    Puri R; Otaegui I; Sabaté M; Serra-Peñaranda A; Puigfel M; Perez de Prado A; Nombela-Franco L; de la Torre Hernandez JM; Ortas Nadal R; Iniguez-Romo A; Jiménez G; Fernandez-Vazquez F; Cuellas-Ramon C; Gonzalo N; Alfonso Jiménez Diaz V; Duocastella L; Molina M; Amoros M; Perez I; Barria Perez A; Pelletier Beaumont E; Nicholls SJ; Garcia Del Blanco B; Rodés-Cabau J
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):435-443. PubMed ID: 28707379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
    Chandrasekhar J; Kok MM; Kalkman DN; Aquino MB; Zocca P; Woudstra P; Beijk MA; Kerkmeijer LS; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Pocock S; von Birgelen C; Mehran R; de Winter RJ;
    JACC Cardiovasc Interv; 2020 Apr; 13(7):820-830. PubMed ID: 32273094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: the ACROSS/TOSCA-4 (Approaches to Chronic Occlusions With Sirolimus-Eluting Stents/Total Occlusion Study of Coronary Arteries-4) trial.
    Kandzari DE; Rao SV; Moses JW; Dzavik V; Strauss BH; Kutryk MJ; Simonton CA; Garg J; Lokhnygina Y; Mancini GB; Yeoh E; Buller CE;
    JACC Cardiovasc Interv; 2009 Feb; 2(2):97-106. PubMed ID: 19463409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
    Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
    J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent: Insights From the DESSOLVE III All-Comers Randomized Trial.
    Takahashi K; Serruys PW; Kogame N; Buszman P; Lurz P; Jessurun GAJ; Koch KT; Troquay RPT; Hamer BJB; Oude Ophuis T; Milewski KP; Hofma SH; Wykrzykowska JJ; Onuma Y; de Winter RJ; Wijns W
    Circ Cardiovasc Interv; 2020 Jun; 13(6):e008737. PubMed ID: 32466676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years.
    Zähringer M; Sapoval M; Pattynama PM; Rabbia C; Vignali C; Maleux G; Boyer L; Szczerbo-Trojanowska M; Jaschke W; Hafsahl G; Downes M; Bérégi JP; Veeger NJ; Stoll HP; Talen A
    J Endovasc Ther; 2007 Aug; 14(4):460-8. PubMed ID: 17696619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
    Tran K; Ullery BW; Kret MR; Lee JT
    Ann Vasc Surg; 2017 Jan; 38():90-98. PubMed ID: 27554688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial.
    Morice MC; Colombo A; Meier B; Serruys P; Tamburino C; Guagliumi G; Sousa E; Stoll HP;
    JAMA; 2006 Feb; 295(8):895-904. PubMed ID: 16493102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective multicenter parallel-controlled trial of TIVOLI biodegradable-polymer-based sirolimus-eluting stent compared to ENDEAVOR zotarolimus-eluting stent for the treatment of coronary artery disease: 8-month angiographic and 2-year clinical follow-up results.
    Xu B; Dou KF; Han YL; Lü SZ; Yang YJ; Huo Y; Wang LF; Chen YD; Wang HC; Li WM; Chen JY; Wang L; Wang Y; Ge JB; Li W; Gao RL
    Chin Med J (Engl); 2011 Mar; 124(6):811-6. PubMed ID: 21518585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sirolimus-eluting versus bare stents after suboptimal infrapopliteal angioplasty for critical limb ischemia: enduring 1-year angiographic and clinical benefit.
    Siablis D; Karnabatidis D; Katsanos K; Kagadis GC; Kraniotis P; Diamantopoulos A; Tsolakis J
    J Endovasc Ther; 2007 Apr; 14(2):241-50. PubMed ID: 17484536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thin Composite-Wire-Strut Zotarolimus-Eluting Stents Versus Ultrathin-Strut Sirolimus-Eluting Stents in BIONYX at 2 Years.
    Buiten RA; Ploumen EH; Zocca P; Doggen CJM; Jessurun GAJ; Schotborgh CE; Roguin A; Danse PW; Benit E; Aminian A; van Houwelingen KG; Schramm AR; Stoel MG; Somi S; Hartmann M; Linssen GCM; von Birgelen C
    JACC Cardiovasc Interv; 2020 May; 13(9):1100-1109. PubMed ID: 32381186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization: 3-Year Outcomes From the Randomized BIOFLOW V Trial.
    Kandzari DE; Koolen JJ; Doros G; Garcia-Garcia HM; Bennett J; Roguin A; Gharib EG; Cutlip DE; Waksman R;
    JACC Cardiovasc Interv; 2020 Jun; 13(11):1343-1353. PubMed ID: 32499026
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.